We are live on ! Find out more

HELP

Helus Pharma Inc. Common Stock

HELP

Market cap $786M

10.76 USD

-0.66

5.78%

At close Updated Oct 6, 4:00 PM EDT

Pre-market

After hours

10.75

-0.01

0.09%

1 day

-5.78%

5 days

-15.28%

1 month

-13.16%

3 months

82.68%

6 months

104.56%

Year to date

29.95%

1 year

67.34%

5 years

-86.77%

10 years

-89.74%

About: Helus Pharma Inc, the commercial operating name of Cybin Inc, is a clinical-stage pharmaceutical company focused on developing proprietary neuroactive compounds, referred to as NSAs, which are synthetic molecules designed to target serotonin pathways. The company's programs are aimed at treating mental health conditions such as depression and anxiety. Its pipeline includes HLP003, which is in clinical development for the adjunctive treatment of depressive disorder, and HLP004, which is in clinical development for generalized anxiety disorder. The company also conducts research on additional investigational compounds.

Employees: 50

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 15%

Neutral 85%

Negative 0%

Helus Pharma Announces Completion of Legal Name Change

NEW YORK and TORONTO, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Helus Pharma (Nasdaq: HELP) (Cboe CA: HELP) (“Helus” or the “Company”), a clinical-stage pharmaceutical company committed to helping minds heal by developing novel serotonergic agonists (“NSAs”), is pleased to announce the Company's legal name has been changed from “Cybin Inc.” to “Helus Pharma Inc.” effective October 1, 2026. The name change was approved by shareholders at the Company's annual and special meeting of shareholders held on September 22, 2026.

Helus Pharma Announces Completion of Legal Name Change

Helus Pharma Eyes Q4 Phase III Data for HLP-003 in Major Depression

Helus Pharma, formerly known as Cybin NASDAQ: HELP, outlined its late-stage development plans for HLP-003 in adjunctive major depressive disorder (MDD) and discussed its broader pipeline of serotonergic agonists during TD Cowen's Novel Mechanisms in Neuropsychiatry virtual summit.

Helus Pharma Eyes Q4 Phase III Data for HLP-003 in Major Depression

Helus Pharma Announces Results of Annual and Special Meeting of Shareholders and Effective Date for Legal Name Change

TORONTO, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Helus Pharma (Nasdaq: HELP) (Cboe CA: HELP) (“Helus” or the “Company”), a clinical-stage pharmaceutical company committed to helping minds heal by developing novel serotonergic agonists (“NSAs”), is pleased to announce the voting results for each of the matters presented at the Company's annual and special meeting of shareholders held on September 22, 2026 (the “Meeting”). There were 107 shareholders represented in person or by proxy at the Meeting holding 46,452,598 common shares, representing 63.58% of Helus's total issued and outstanding common shares as at the record date for the Meeting. The voting results for each matter presented at the Meeting are set out below.

Helus Pharma Announces Results of Annual and Special Meeting of Shareholders and Effective Date for Legal Name Change

Cybin Inc. (HELP) Shareholder/Analyst Call Prepared Remarks Transcript

Cybin Inc. (HELP) Shareholder/Analyst Call Prepared Remarks Transcript

Cybin Inc. (HELP) Shareholder/Analyst Call Prepared Remarks Transcript

Cybin Shareholders Weigh Helus Pharma Rebrand, Eight-Member Board

Cybin NASDAQ: HELP, doing business as Helus Pharma, held its Annual General and Special Meeting of Shareholders, where shareholders were asked to consider resolutions related to the company's auditor, board size, corporate name and director elections.

Cybin Shareholders Weigh Helus Pharma Rebrand, Eight-Member Board

Helus Pharma to Participate at the TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit

CEO Michael Halstead to participate in a fireside chat on September 23, 2026 at 9:00 a.m. EDT CEO Michael Halstead to participate in a fireside chat on September 23, 2026 at 9:00 a.m. EDT

Helus Pharma to Participate at the TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit

Helus Pharma Presents New Analyses on HLP003 in Major Depressive Disorder at Psych Congress 2026

Poster presentations further characterize clinical profile of HLP003 and Phase 3 PARADIGM program evaluating HLP003 as a potential adjunctive treatment for major depressive disorder (“MDD”) NEW YORK and TORONTO, Sept. 21, 2026 (GLOBE NEWSWIRE) -- Helus Pharma (Nasdaq: HELP) (Cboe CA: HELP) (the “Company” or “Helus Pharma”), a clinical-stage pharmaceutical company committed to helping minds heal by developing novel serotonergic agonists (“NSAs”), today announced the presentation of four posters evaluating HLP003, an investigational oral deuterated psilocin analog being developed as an adjunctive treatment for MDD, at Psych Congress 2026, September 15–19, 2026, at the Ernest N.

Helus Pharma Presents New Analyses on HLP003 in Major Depressive Disorder at Psych Congress 2026

Cybin Eyes Q4 Phase 3 Data for Depression Drug HLP003

Cybin NASDAQ: HELP executives outlined plans for its late-stage depression program, including an expected fourth-quarter Phase 3 data readout for HLP003, during H.C. Wainwright's 28th Annual Global Investment Conference.

Cybin Eyes Q4 Phase 3 Data for Depression Drug HLP003

Cybin Eyes Q4 Phase III Depression Readout as Psychedelic Pipeline Advances

Helus Pharma Chief Executive Officer Michael Halstead said the company expects a pivotal Phase III readout for its HLP003 program in adjunctive major depressive disorder in the fourth quarter, describing the data as a key near-term catalyst for the company's mental health treatment pipeline.

Cybin Eyes Q4 Phase III Depression Readout as Psychedelic Pipeline Advances

Cybin Inc. (HELP) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Cybin Inc. (HELP) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Cybin Inc. (HELP) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

See News Rankings

Price charts implemented using Lightweight Charts™